Masahiro Yokoyama

Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis

Daisuke Ennishi, Yoshinobu Maeda, Nozomi Niitsu et al. · Blood · 2010 · 153 citations · Full text

Medicine, Hematology, Oncology +16

Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation

Kengo Takeuchi, Masahiro Yokoyama, Shin Ishizawa et al. · Blood · 2010 · 128 citations · Full text

Medicine, Oncology, Pathology +14

Prognostic impact of extranodal involvement in diffuse large B‐cell lymphoma in the rituximab era

Hiroyuki Takahashi, Naoto Tomita, Masahiro Yokoyama et al. · Cancer · 2011 · 104 citations · Full text

Medicine, Internal Medicine, Oncology +14

Central nervous system event in patients with diffuse large B‐cell lymphoma in the rituximab era

Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto et al. · Cancer Science · 2011 · 88 citations

Medicine, Oncology, Cancer Immunology +9

BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation

Naoko Tsuyama, Seiji Sakata, Satoko Baba et al. · Blood · 2017 · 86 citations · Full text

Medicine, Cancer Biology, Molecular Biology +13